A Post-Authorization Safety Study of Interferon Beta Therapy in Participants With Multiple Sclerosis

Subcutaneous (SC) Interferon Beta Therapy in Multiple Sclerosis Patients and Characterization of Injection Site Reactions and Flu-Like Symptoms Under Daily Practice Setting

The purpose of this study is to investigate the safety of subcutaneous (SC) interferon beta therapies with regard to frequency of injection site reactions (ISR) and flu-like symptoms (FLS) as reported by the relapsing-remitting multiple sclerosis (RRMS) participants.

Key Inclusion Criteria:

• Ability to understand the purpose of the study and provide signed and dated informed consent
• Diagnosed relapsing-remitting multiple sclerosis
• Currently receiving a SC interferon beta treatment (label conform)
• Stable on SC interferon beta treatment for three months or longer (switch between SC interferon beta treatments possible).

Key Exclusion Criteria:

• Contraindications according to the Fachinformation (German equivalent to Summary of Product Characteristics [SmPC])
• Treatment with Glatiramer acetate and intramuscular (IM) interferon beta-1a
• Participation in a non-interventional or interventional clinical study of Biogen